Treatment for Depression with Positive Allosteric Modulator of AMPA
Summary
The European Patent Office published patent application EP4149478A1 for Takeda Pharmaceutical Company Limited, covering a treatment for depression using a positive allosteric modulator of AMPA (AMPA receptor). The patent was published on April 1, 2026, with inventors including Pathi Jagannatham, Naga Venkatesha Murthy, Asgharnejad Mahnaz, and Xu Lin. The designated states include 27 European countries covering major pharmaceutical markets.
What changed
EPO published patent EP4149478A1 for Takeda Pharmaceutical covering pharmaceutical compositions comprising positive allosteric modulators of AMPA for treating depression (A61P 25/24). The patent application includes claims to methods of treatment and pharmaceutical formulations.
Pharmaceutical companies developing CNS therapeutics should review this patent landscape for freedom-to-operate considerations. Generic manufacturers and biotech firms researching AMPA receptor modulators may need to assess potential licensing requirements or design-around strategies.
What to do next
- Monitor for updates
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TREATMENT FOR DEPRESSION WITH A POSITIVE ALLOSTERIC MODULATOR OF AMPA
Publication EP4149478A1 Kind: A1 Apr 01, 2026
Applicants
Takeda Pharmaceutical Company Limited
Inventors
PATHI JAGANNATHAM, Naga Venkatesha, Murthy, ASGHARNEJAD, Mahnaz, XU, Lin
IPC Classifications
A61K 31/549 20060101AFI20211119BHEP A61P 25/24 20060101ALI20211119BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.